CA
NZ
UK
AU
IND
US
Jim A. Swanson, Executive Vice President and CFO of Columbia Sportswear Co, filed a Form 4 on November 4, 2026, disclosing option exercises and an open-market sale of common stock that occurred on November 3, 2026.
Jeremy Brett Sokolove, Chief Medical Officer of Vor Biopharma Inc., filed a Form 4 on November 4, 2026, disclosing that 1,917 shares of common stock were withheld on November 2, 2026, to cover tax obligations tied to the vesting of restricted stock units.
Burt W. Podbere, Chief Financial Officer of CrowdStrike Holdings, Inc. (NASDAQ:CRWD), filed a Form 4 on November 4, 2026, disclosing three dispositions of Class A common stock totaling 7,710 shares on November 2, 2026.
Sean McNealy, a director and 10% owner of Abacus Global Management, Inc. (NYSE:ABX), filed a statement of changes in beneficial ownership on November 4, 2026, disclosing a transaction dated October 30, 2026 involving a contribution of common stock to the Fidelity Exchange Fund and …
Director Sameer K. Gandhi filed a Form 4 with the SEC on November 4, 2026, disclosing the sale of 14,000 shares of CrowdStrike Holdings, Inc. Class A common stock on November 2, 2026, executed through Potomac Investments L.P. - Fund 1 pursuant to a …
George Kurtz, President and CEO of CrowdStrike Holdings, Inc., filed a Form 4 on November 4, 2026, disclosing the sale of Class A common stock on November 2 and November 3, 2026, through both direct sales and transactions under a Rule 10b5-1 plan.
Matthew Ganovsky filed a Form 4 with the SEC on November 4, 2026, disclosing a disposition of 28,027 shares of Abacus Global Management, Inc. common stock on October 30, 2026, through a contribution to the Fidelity Exchange Fund.
Director and 10% owner Kevin Scott Kirby filed a Form 4 with the SEC on November 4, 2026, disclosing a disposition of 28,027 shares of Abacus Global Management, Inc. common stock on October 30, 2026, through a contribution to the Fidelity Exchange Fund.
Director Rami Qasem of KBR, Inc. filed a statement of changes in beneficial ownership on November 4, 2026, disclosing the acquisition of 4,410 restricted stock units of KBR common stock on November 2, 2026.
Director Kim R. Tsuchimoto of Monopar Therapeutics filed a Form 4 on November 4, 2026, disclosing a series of stock option exercises and open-market sales of common stock executed on November 2 and November 4, 2026, pursuant to a Rule 10b5-1 plan.
Please wait processing your request...